AnaptysBio Board Member's Planned Stock Sale Follows RSU Vesting
Rhea-AI Filing Summary
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,015 shares
Net Sell
1 txn
Insider
FENTON DENNIS M
Role
Director
Sold
3,015 shs ($72K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,015 | $23.97 | $72K |
Holdings After Transaction:
Common Stock — 4,965 shares (Direct)
Footnotes (2)
- F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024.
- F2. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Was ANAB insider Dennis Fenton's stock sale planned in advance?
Yes, the sale was executed pursuant to a Rule 10b5-1 trading plan that Dennis Fenton adopted on March 22, 2024. This indicates it was a pre-planned transaction rather than a spontaneous sale.
What is Dennis Fenton's role at ANAB?
Dennis Fenton serves as a Director on AnaptysBio's Board of Directors, as indicated by the 'X' marked in the Director box on the Form 4 filing.